I am very reluctant to answer this. The company annct suggests...

I am very reluctant to answer this. The company annct suggests 2028 will have revenue, and various other comments suggest it will take some time to reach full market penetration. So in terms of sp appreciation from revenue receipt thats a way off.
we are more likely to see sp appreciation once we get efficacy signals, and that could be anytime with rp11, and once trials start in the kidney there is a biomarker that will help, and that is sometime next year.
So the smart money will be accumulating now as these milestones might see us around 50c sometime next year. That’s quite a jump.
If you read some of hottods more detailed posts you will get a clearer picture. An advanced search should find the posts.